Newsbenzinga
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
· Published
Article summary
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanced cutaneous melanoma.
An excerpt from the original article.
Comments —
Loading comments…